In a joint statement on September 30, 2018, the United States
and Canadian Governments announced that they reached an agreement,
alongside Mexico, on a new, modernized trade agreement for the
21st century.1 The pending trilateral
deal, called the United States-Mexico-Canada Agreement (USMCA), is
intended to replace the North American Free Trade Agreement (NAFTA)
currently in force.
The text of the USMCA was published on the Office of the United
States Trade Representative website shortly after the formal
agreement was announced.2 The deal includes updated
provisions governing the protection and enforcement of intellectual
property (IP) rights which, if ratified, will modify the legal and
regulatory landscape for the pharmaceutical industry in Canada,
notably in the field of biologics. The following is a summary of
what is new and what will likely remain the same after the USMCA
comes into force.